In June 2004, Argos signed a collaboration agreement with Kirin Brewery’s
Pharmaceutical Division for developing therapies using dendritic cells.
Under the terms of the agreement, the companies will collaborate to develop
and commercialize dendritic cell vaccines, initially in the areas of
cancer and infectious diseases. Argos and Kirin will jointly conduct
and development and will share profits worldwide. Argos will commercialize
in the United States and Canada, Kirin will commercialize in key Asian
markets, and opportunities in Europe, Latin America and other global
regions will be determined jointly.
In March 2004, Argos entered into a licensing transaction with Geron
Corporation, in which Argos received Geron stock in exchange for granting
co-exclusive right to use Argos’ platform technology in specific
therapeutic cancer vaccines using telomerase and other defined antigens.
Argos retains co-exclusive rights to use the platform technology with
defined antigens, and exclusive rights to use it with total tumor RNA
Argos is collaborating with top global institutions and investigators listed
below for the purpose of conducting preclinical and clinical research in the
|Chronic Lymphocytic Leukemia
| Duke Univ.
|| Eli Gilboa
|| Dendritic cell research
Future Partnership Opportunities
Argos’ partnership with Kirin is initially focused on developing
and commercializing dendritic cell-based vaccines in the areas of cancer
and infectious diseases. Opportunities outside of US, Canadian and Asian
markets will be determined jointly and may result in additional partnerships
or strategic alliances. In addition, the parties may in the future seek
a partner for the development of therapeutic vaccines for infectious
Argos is currently seeking a partner for its monoclonal antibody-based
therapy for lupus and is in discussions with a number of potential partners.
For information on these, or other partnership opportunities,